The tumor suppressor Ras-association domain family member 6 (RASSF6) has Ras-association domain (RA) and Salvador/RASSF/Hippo domain (SARAH). RASSF6 antagonizes MDM2, stabilizes p53, and induces apoptosis and cell cycle arrest. We previously demonstrated the interaction between RASSF6 and MDM2, but did not determine how both proteins interact with each other. We have shown here that N-terminal, RA, and SARAH domains of RASSF6 interact with MDM2 at distinct regions. RA binds to the RING-finger region of MDM2 and stabilizes p53. SARAH binds RA and blocks the interaction between RA and MDM2. RA overexpression induces p53-dependent apoptosis and senescence. In the presence of active KRas, the interaction between RA and MDM2 is recovered. In this way, RA and SARAH play an important role in Rasmediated regulation of p53.
Ras-association domain family member 6 (RASSF6) is a member of Ras-association (RA) domain family [1] . RASSF6 harbors a RA domain, a Salvador/RASSF/ Hippo (SARAH) domain, and a PDZ-binding motif. RASSF6 expression is suppressed by CpG island methylation in acute and chronic lymphocytic leukemia, neuroblastoma, malignant melanoma, and gastric cancer [2] [3] [4] [5] . The low expression of RASSF6 correlates with disease progression in gastric cancer and pancreatic cancer [6, 7] . RASSF6 depletion hampers DNA repair after DNA damage and causes genomic instability [8] . These findings support that RASSF6 is a tumor suppressor like other RASSF proteins.
We previously reported that RASSF6 induces caspase-dependent and caspase-independent apoptosis [9] . We also revealed that RASSF6 and mammalian Ste20-like kinases (MST), the components of the tumor-suppressive Hippo pathway, form a complex under the basal condition and that MST kinases suppress RASSF6-induced apoptosis, whereas RASSF6 blocks MST kinase activation [10] . When cells are exposed to stress, RASSF6 and MST kinases are dissociated, so that RASSF6-mediated apoptosis is triggered and the Hippo pathway is activated. In this manner, RASSF6 co-operates with the Hippo pathway.
The underlying mechanism by which RASSF6 induces apoptosis is not yet fully understood. RASSSF6 interacts with modulator of apoptosis-1 (MOAP-1) and activates Bax [10, 11] . RASSF6 induces the nuclear translocation of apoptosis-inducing factor and endonuclease G [9] . In human colon cancer HCT116 cells, UV exposure enhances p53 expression to induce apoptosis and cell cycle arrest, while RASSF6 depletion reduces UV-induced increase in p53 [8] . The additional depletion of MDM2 or the treatment with nutlin-3, an inhibitor of MDM2, recovers p53 expression. These findings suggest that RASSF6 regulates p53 expression via MDM2. As a matter of fact, RASSF6 interacts with MDM2. However, the molecular determinant of the interaction between RASSF6 and MDM2 and the mechanism how RASSF6 protects p53 from MDM2-mediated degradation are still unclear. In this study, we examined how RASSF6 and MDM2 interact with each other and revealed the importance of the RA domain.
Materials and methods

DNA constructions and virus production
pCIneoFLAG-His6-FLAG (pCIneoFHF), pCIneoMyc, pCIneoGreen fluorescent protein (GFP), pCIneoGFP-RASSF6, pCIneoFHF-MDM2, pCIneoMyc-p53, pQCXIP EF, and pCIneoFLAG-MOAP-1 were described previously [8] . PCR was performed with the primers (H2842, 5 0 -gct agccaccatggtgagcaagggcgagga-3 0 and H2843, 5 0 -gaattccttgta cagctcgtccatgccgcc-3 0 ) on pmCherry-N1 (Takara Bio USA, Inc., Mountain View, CA, USA). The product was digested with NheI/EcoRI and ligated into the same sites of pCIneo (Promega, Fitchburg, WI, USA) to generate pCIneomCherry. Various RASSF6 and MDM2 deletion constructs were prepared by PCR and contain the following amino acids; MDM2, 1-491; MDM2-N, 1-238; MDM2-M, 238-436; MDM2-C, 436-491; MDM2-N+M, 1-436; and MDM2-M+C, 238-491. RASSF6, 1-369; RASSF6-del C, 1-308; RASSF6-N, 1-217; RASSF6-del N, 212-369: RASSF6-RA, 212-308; RASSF6-C, 301-369; and RASSF6-del RA, 1-213 and 305-369 (Fig. 1A) . NheI/NotI fragments from various pCIneoGFP-RASSF6 vectors were ligated into XbaI/NotI sites of pQCXIP EF to generate retrovirus vectors. pEF-BOS-Myc-Ki-Ras DA, pEF-BOS-Myc-Ki-Ras DN, pLL4.0-HRas-V12, and pIRM21-Flag-N-Ras-V12 are gifts of Yoshimi Takai (Kobe University), Kentaro Nakagawa (MSD), and Michiyuki Matsuda (Kyoto University). pEF-BOS-Myc-Ki-Ras DA and pEF-BOS-Myc-Ki-Ras DN contain mutated human Ki-Ras genes, in which Glycine12 and Serine17 are replaced with Valine and Asparagine, respectively. PCR was performed on pLL4.0-HRas-V12 with the primers (H2634, 5 0 -gaattcggagcgatgacggaatataa gctg-3 0 and H2635, 5 0 -gtcgactaggagagcacacacttgcagct-3 0 ).
The product was ligated into pCIneoFH to generate pCIneoFH-HRas DA.
Antibodies and reagents
The antibodies and the reagents were obtained from com- 
Apoptosis and senescence
Various RASSF6 proteins were expressed in HCT116 cells. The cells were immunostained with anti-cytochrome C antibody and the nuclei were visualized with Hoechst 33342. The cytochrome C release and the nuclear condensation were evaluated. Senescence was evaluated in TIG-3 cells expressing various GFP-RASSF6 proteins by use of a senescence b-galactosidase staining kit (Cell Signaling Technology).
RNA interference
RNA interferences were performed by use of Lipofectamine RNAiMAX (Thermo Fisher Scientific). The small interfering (si) RNAs used are; Silencer Select negative control no. 2 and human p53, s606 (Ambion Ò ; Thermo Fisher Scientific).
Quantitative RT-PCR
Quantitative RT-PCR was performed in HCT116 cells to detect BTG2 and CDKN1A as described previously [8] . 
Reporter assay
For the NFjB reporter assay, HEK293 cells were transfected with pIgΚ cona luciferase reporter (a gift of S. Yamaoka, Tokyo Medical and Dental University) and pCMV alkaline phosphatase (a gift of S. Watanabe, The University of Tokyo) with various RASSF6 retrovirus vectors. The cells were treated with 0.1 ngÁmL À1 of tumor necrosis factor-a (TNF-a). Luciferase activity was assayed as described previously [12] .
Statistical analysis
Statistical analyses were performed with Student's t test for comparison between two samples and analysis of variance with Bonferroni's post hoc test for multiple comparisons using GRAPHPAD PRISM software (GraphPad Software, Inc., La Jolla, CA, USA).
Results
Molecular determinants involved in the interaction between RASSF6 and MDM2
To determine which regions of RASSF6 and MDM2 are required for the interaction, we performed a series of coimmunoprecipitation experiments using various deletion constructs of RASSF6 and MDM2 (Fig. 1A ). RASSF6 interacts with the N-terminal region containing the p53-binding domain, the middle region containing the acidic domain, and the C-terminal RING-finger domain of MDM2 (Fig. 1B ) [13] . Conversely MDM2 interacts with the N-terminal, RA, and SARAH domains of RASSF6 (Fig. 1C) . The N-terminal region and RA domain of RASSF6 bind the middle region and C-terminal region of MDM2, respectively ( Fig. 2A,B) . The SARAH domain of RASSF6 does not bind either the N-terminal, middle, or C-terminal region of MDM2 (Fig. 2C , left) but interacts with MDM2-N+M, suggesting that the border between the N-terminal and middle regions may be important (Fig. 2C , right). All these findings indicate that RASSF6 and MDM2 interact with each other at multiple sites.
MOAP-1 interacts with the N-terminal region of RASSF6
MOAP-1 is also important in RASSF6-induced apoptosis, but the interacting region is not yet determined [10, 11] . The interaction between MOAP-1 and RASSF1A is mediated by the basic sequence of MOAP-1 and the C-terminal acidic sequence of RASSF1A [14] . However, RASSF6 does not have this acidic sequence. There exists another report that the RASSF1A mutant, in which Cysteine 65 is mutated to Arginine, fails to interact with MOAP-1 [15] . This observation suggests that MOAP-1 interacts with the N-terminal region of RASSF1A. To determine which region of RASSF6 is involved in the interaction with MOAP-1, we coexpressed MOAP-1 with the fulllength GFP-RASSF6 and various deletion constructs of GFP-RASSF6, and performed the immunoprecipitation with anti-GFP antibody (Fig. S1A ). RASSF6-del C and RASSF6-N interact with MOAP-1 (Fig. S1A, arrows) , while the RA domain or the SARAH domain does not. That is, MOAP-1 binds to the N-terminal region of RASSF6. We next tested the effect of MDM2 on the interaction between MOAP-1 and RASSF6. FLAG-RASSF6 was coexpressed with Myc-MOAP-1 and was immunoprecipitated. Myc-MDM2 did not reduce but rather enhance the amount of the coimmunoprecipitated MOAP-1 (Fig. S1B ).
The RA domain of RASSF6 is important for the stabilization of p53
We next expressed various FLAG-tagged RASSF6 deletion proteins with Myc-tagged p53 to examine which regions of RASSF6 enhance p53 expression. RASSF6-N enhanced p53 at the same level as the fulllength of RASSF6 (Fig. 3A , the second and third lanes in the top panel). RASSF6-del N slightly enhanced it (Fig. 3A , the fourth lane), but RASSF6-del RA did not enhance p53 expression (Fig. 3A , the fifth lane). We confirmed the interaction between RASSF6-del RA and MDM2 and excluded the possibility that RASSF6-del RA failed to interact with MDM2 and to stabilize p53 (data not shown). We speculated that the RA domain, which binds to the Cterminal RING-finger domain of MDM2, is critical for the inhibition of p53 degradation. Indeed, when p53 was expressed in HEK293 cells and the cells were treated with cycloheximide, p53 underwent degradation in a time-dependent manner (Fig. 3B , the left). But under coexpression of the RA domain of RASSF6, p53 was stabilized (Fig. 3B , the right). Moreover, even when MDM2 was coexpressed, p53 was stabilized by the RA domain (Fig. 3C) . We previously reported that RASSF6 augments self-ubiquitination of MDM2 and postulated that RASSF6 might induce MDM2 degradation and eventually up-regulate p53 [2] . However, we unexpectedly found that the RA domain stabilized MDM2 (Fig. 3C) . Therefore, we next hypothesized that RASSF6 inhibits the interaction between MDM2 and p53. The phosphorylation at Serine15 is reported to reduce the interaction between MDM2 and p53 [16] . Therefore, we expressed Mycp53 with RASSF6 and RASSF6-RA, and immunoblotted the cell lysates with anti-phospho-p53 (Ser15) antibody. At first glance, the phosphorylation was enhanced (Fig. 3D , the second panel). As p53 expression was more remarkably enhanced (Fig. 3D , the first panel), we could not conclude that RASSF6 or RASSF6-RA increases the phosphorylation at Serine15. To more directly evaluate the interaction between MDM2 and p53, the coimmunoprecipitation experiment was performed. It demonstrated that in the presence of the RA domain, the interaction between p53 and MDM2 was rather strengthened (Fig. 3E) . All in all, these findings do not support that the RA domain stabilizes p53 through either the decrease in MDM2 or the inhibition of the interaction between MDM2 and p53, and rather suggest that the RA domain prevents p53 degradation in the complex of p53 and MDM2.
The SARAH domain of RASSF6 negatively regulates the RASSF6-mediated stabilization of p53
Of note, the effect of RASSF6-del C was more remarkable than the full-length RASSF6 (Fig. 3A , the sixth lane, a black arrow in the top panel). This finding prompted us to hypothesize that the SARAH domain functions as an autoinhibitory region. The SARAH domain is known to form oligomers [17] , but the SARAH domain binds RASSF6-del C and RASSF6-RA, both of which lack the SARAH domain (Fig. 3F) . More importantly, the SARAH domain attenuates the interaction of MDM2 with RASSF6, RASSF6-del C, and RASSF6-RA (Fig. 3G) . These findings suggest that the SARAH domain interferes with the interaction of the RA domain with MDM2, so that it compromises the inhibitory effect of RASSF6 on the MDM2-mediated degradation of p53.
Ras signaling recovers the SARAH-reduced interaction between the RA domain and MDM2
Oncogenic Ras induces permanent cell cycle arrest via p53 [18] . We examined the effect of KRas on the stabilization of p53 and on the molecular interaction. Consistent with the inhibitory effect of the SARAH domain on the interaction between the RA domain and MDM2, coexpression of the SARAH domain canceled the RA domain-dependent enhancement of p53 expression (Fig. 4A, the third lane) . However, when the dominant active KRas was further coexpressed, the p53 expression was enhanced again (Fig. 4A , the fourth lane). We reasoned that the dominant active KRas releases the RA domain from the inhibition by the SARAH domain. To address this question, we examined the interaction of RASSF6 with MDM2 under coexpression of RASSF6-SARAH alone or with KRas (Fig. 4B) . The SARAH domain inhibited the interaction of MDM2 with RASSF6-full and RASSF6-RA, but the dominant active KRas recovered the interaction (Fig. 4B , the left for RASSF6-full and the right for RASSF6-RA). Based on these findings, we further hypothesized that the dominant active KRas inhibits the binding of the SARAH domain to the RA domain and release the RA domain from the auto-inhibitory regulation by the SARAH domain. However, contrary to our expectation, the interaction between the RA domain and the SARAH domain was still observed in the presence of the dominant active KRas (Fig. 4C) . In Fig. 4B , the amount of the SARAH domain coimmunoprecipitated with FLAG-MDM2 increased in the presence of the dominant active KRas. This finding implies that in the presence of the dominant active KRas, the complex composed of the SARAH and RA domains was not dissociated and bound more tightly to MDM2. We also tested HRas and NRas (Fig. S2) . NRas recovered the interaction between MDM2 and RASSF6, while HRas did not. Under the same condition, KRas, whose expression was relatively low, clearly recovered the interaction and also increased the amount of the coimmunoprecipitated SARAH domain.
The RA domain is important for caspasedependent apoptosis, UV-induced apoptosis, p53-dependent senescence, and p53-target gene transcription
To further confirm the importance of the RA domain, we examined the effect of RASSF6-RA and RASSF6-del RA on apoptosis, senescence, and p53-target gene expression. RASSF6-RA induced apoptosis in HCT116 cells, whereas RASSF6-del RA did not (Fig. 5A) . zVAD-FMK, a pan-caspase inhibitor, and p53 knockdown attenuated RASSF6-RA-induced apoptosis (Fig. S3A,B) . To study senescence, we used human fibroblast TIG-3 cells and expressed GFP-RASSF6 and GFP-RASSF6-RA by use of retrovirus vectors. RASSF6 and RASSF6-RA induced senescence in TIG-3 cells, and p53 knockdown blocked it (Fig. 5B) . RASSF6-del RA suppressed apoptosis in the cells exposed to UV (Fig. 5C ). qRT-PCR data indicated that RASSF6-RA up-regulated the expression of p53-target genes such as BTG2 and CDKN1A, whereas RASSF6-del RA did not (Fig. 5D ). All these findings support that the RA domain is important for caspase-dependent apoptosis and p53-dependent events.
Not only the RA domain but also other regions are involved in the regulation of NFjΒ signaling RASSF6 suppresses NFjΒ signaling and is implicated in TNF-a-induced apoptosis [10, 11] . We raised a question whether and how each domain of RASSF6 is involved in the regulation of NFjB signaling. In HEK293 cells, NFjB reporter activity was up-regulated in response to TNF-a (Fig. S4) . RASSF6 suppressed TNF-a-induced reporter activity. We also tested RASSF6-del RA, RASSF6-del C, and RASSF6-RA. All of them suppressed TNF-a-induced reporter activity.
Discussion
MDM2 is the most prominent regulator of p53 [13] . MDM2 directly inhibits p53 transactivation, and ubiquitinates p53 to induce its proteasome-dependent degradation. We previously reported that RASSF6 depletion reduces p53 expression and that this reduction depends on MDM2 [8] . These findings imply that RASSF6 suppresses the MDM2-dependent degradation of p53. Indeed, RASSF6 interacts with MDM2 and inhibits MDM2-mediated degradation of p53 to induce apoptosis and cell cycle arrest in a p53-dependent manner. The interaction between RASSF6 and MDM2 is instrumental for the role of RASSF6 as a tumor suppressor.
In this study, we conducted the detailed analysis of the interaction between RASSF6 and MDM2. We first revealed that RASSF6 and MDM2 interact with each other through more than one site. The N-terminal region and the RA domain bind to the central region and the C-terminal RING finger domain of MDM2, respectively (Figs 1 and 2) . The SARAH domain binds to neither the N-terminal nor the central region of MDM2, but it does bind to the deleted construct covering both the N-terminal and central regions, suggesting that the SARAH domain may bind to the border region between these two regions (Fig. 2) . It does not necessarily mean that one RASSF6 and one MDM2 interact with each other via multiple sites simultaneously. Both of RASSF6 and MDM2 form a homo-oligomer [1, 19] . It is possible that one RASSF6 binds to the one region of MDM2, while the second RASSF6 binds to the other region of the same MDM2 or the distinct MDM2, and thus, RASSF6 and MDM2 may form a complex of multiple molecules. The N-terminal region of MDM2 binds to the N-terminal transactivation domain of p53 to directly suppress the transactivation [20] . The second interaction, which is mediated by the central region of MDM2 and the central DNAbinding domain of p53, is important for p53 ubiqutination [21] [22] [23] . Furthermore, the C terminus of p53 binds to the N-terminal region of MDM2 [24] .
Although the central region of MDM2 may be shared by p53 and RASSF6, the p53-binding N-terminal site is located within the initial 100 amino acid residues of MDM2 and is not likely to be overlapped by the RASSF6-binding site, which is predicted to exist in the border region between the N and middle regions of MDM2. Consistently RASSF6 does not block the interaction between MDM2 and p53 (Fig. 3E) . p53 is regulated by post-translational modifications, including phosphorylation and acetylation. It is intriguing to examine the effect of RASSF6 on these modifications of p53. In this study, we examined the effect of RASSF6 on the phosphorylation at Serine15, which is reported to regulate the interaction between MDM2 and p53 [16] . RASSF6 and RASSF6-RA increased the phosphorylation (Fig. 3D) . However, considering the increase in p53 expression, we did not conclude that RASSF6 increases the phosphorylation at this site. The coimmunoprecipitation experiment indicates that RASSF6 strengthens the interaction between MDM2 and p53 (Fig. 3E ). In conclusion, RASSF6 stabilizes p53 even under the condition that p53 interacts with MDM2.
During the experiments, we noticed that the RASSF6 mutant lacking the RA domain, although it still binds MDM2, fails to enhance p53 expression (Fig. 3A) . As the RA domain binds to the C-terminal RING-finger domain of MDM2, it is reasonable to Fig. 3 . The effect of RASSF6-deleted proteins on the expression of p53 and MDM2. (A) HEK293 cells were transfected with pCIneoMycp53 and either various pCIneoFHF-RASSF6 constructs or control pCIneoFHF. Forty-eight hours after transfection, the cell lysates were immunoblotted with anti-Myc, anti-FLAG, and anti-b-actin antibodies. FLAG-RASSF6, FLAG-RASSF6-N, and FLAG-RASSF6-del N slightly enhanced the expression of p53, while FLAG-RASSF6-del RA had no effect. In contrast, FLAG-RASSF6-del C remarkably enhanced the expression of p53 (a black arrow). White arrowheads demonstrate FLAG-RASSF6 proteins. (B) HEK293 cells were transfected with pCIneoMyc-p53 and either pCIneo-GFP or pCIneoGFP-RASSF6-RA. Forty-eight hours after transfection, the cells were treated with cycloheximide for the indicated periods of time (0, 4, 8, 12, and 24 h). The cell lysates were immunoblotted with anti-Myc, anti-GFP, and anti-b-actin antibodies. Myc-p53 decreased in a time-dependent manner (the left), but coexpression of GFP-RASSF6-RA blocked the degradation of p53 (the right). (C) The degradation of Myc-P53 was evaluated under coexpression of FLAG-MDM2 as described for (B). GFP-RASSF6-RA stabilized not only Myc-p53 but also FLAG-MDM2. (D) HEK293 cells were transfected with pCIneoMyc-p53 and one of pCIneoGFP, pCIneoGFP-RASSF6, and pCIneoGFP-RASSF6-RA. Forty-eight hours later, the cell lysates were immunoblotted with anti-Myc and anti-phospho-p53 (Ser15) antibodies. An arrow indicates the signal. An asterisk demonstrates nonspecific signals, whose sizes are smaller than the signals detected with anti-Myc antibody. (E) HEK293 cells were transfected with various combinations of control FLAG, FLAG-MDM2, GFP-p53, and GFP-RASSF6-RA. Immunoprecipitation was performed with anti-DYKDDDDK-tag beads. The beads were washed with buffer A. Inputs and immunoprecipitates were immunoblotted with anti-FLAG and anti-GFP antibodies. GFP-RASSF6-RA did not inhibit the interaction between FLAG-MDM2 and GFP-p53, and rather enhanced it. An asterisk indicates immunoglobulin heavy chains. (F) mCherry-RASSF6-C was expressed in HEK293 cells with control GFP and various GFP-RASSF6 proteins. Immunoprecipitation was performed with anti-GFP antibody prefixed on protein G sepharose 4 fast flow beads. The beads were washed with buffer A. Inputs and immunoprecipitates were immunoblotted with anti-GFP and anti-mCherry antibodies. mCherry-RASSF6-C was coimmunoprecipitated with GFP-RASSF6, GFP-RASSF6-del C, and GFP-RASSF6-RA (arrows). (G) HEK293 cells were transfected with various combinations of GFP-RASSF6, GFP-RASSF6-del C, GFP-RASSF6-RA, mCherry-RASSF6-C, FLAG-MDM2, and control FLAG. Immunoprecipitation was performed with anti-DYKDDDDK-tag beads. The beads were washed with buffer A. Inputs and immunoprecipitates were immunoblotted with anti-FLAG, anti-GFP, and anti-mCherry antibodies. GFP-RASSF6, GFP-RASSF6-del C, and GFP-RASSF6-RA were coimmunoprecipitated with FLAG-MDM2, and mCherry-RASSF6-C decreased the amount of coimmunoprecipitated GFP-RASSF6 proteins (arrows).
posit that the RA domain is important to suppress MDM2-mediated degradation of p53. Consistent with this assumption, in the presence of the RA domain, p53 is stabilized (Fig. 3B) . As the ubiquitinated p53 was not clearly detected even in MG-132-treated cells and even with the coexpression of MDM2 (data not shown), we could not discuss whether RASSF6 and the RA domain block the ubiquitination of p53 or the degradation of the ubiquitinated p53. However, as RASSF6 mutant lacking the RA domain does not enhance p53 expression, at least it can be concluded that the RA domain is important for RASSF6 to block p53 degradation. Consistently, the RA domain causes apoptosis and senescence in p53-dependent manner and induces p53-target gene expression (Fig. 5) .
We also found that RASSF6 mutant lacking the SARAH domain more remarkably enhances p53 expression than RASSF6 itself (Fig. 3A) . This finding implies that the SARAH domain inhibits the function of the RA domain against MDM2-mediated p53 degradation. As expected, we detected the interaction of the SARAH domain with the RA domain. The RA domain does not enhance p53 expression as well as RASSF6 mutant lacking the SARAH, which is composed of the N-terminal and RA domains, suggesting the interaction mediated by the N-terminal region of RASSF6 is also important to suppress MDM2 activity.
RASSF proteins are implicated in Ras-dependent cell death and senescence [25, 26] . Considering the importance of the RA domain in the regulation of MDM2, we examined whether and how Ras protein affects the effect of the RA domain. We coexpressed the dominant active and negative KRas with the SARAH and RA domains (Fig. 4A) . The dominant active KRas recovered the effect of the RA domain in the presence of the SARAH domain. The interaction study also revealed that the interaction between the RA domain and MDM2 is recovered by the dominant active KRas under coexpression of the SARAH domain (Fig. 4B) . We initially surmized that KRas interferes with the intramolecular interaction between the RA and SARAH domains. But our hypothesis was not supported. In the presence of the dominant active KRas, the RA domain still interacts with the SARAH domain but even so, regains the binding ability to MDM2 (Fig. 4C) . The RA domain simultaneously interacts with the C-terminal RING-finger domain of MDM2 (for simplicity, we depict this as MDM2-C), and the SARAH domain of RASSF6 under the coexpression of KRas, which indicates that the SARAH-and MDM2-C-binding sites are not overlapped. However, the SARAH domain attenuates the binding of MDM2-C to the RA domain without KRas, these sites may be close to each other. If this is the case, the two molecules may have some difficulty to bind to the RA domain side by side. We speculate that the binding of KRas induces the conformational change in the RA domain. Consequently, the SARAH domain-binding and MDM2-C-binding sites are shifted and separated, so that both of the SARAH domain and MDM2-C comfortably bind to the RA domain (Fig. S5) . Interestingly, NRas also shows a similar effect, but more weakly (Fig. S2) . HRas does not show any effect. This finding suggests that each Ras protein may bind to the RA domain in a distinct manner. Further detailed studies will be important.
Additionally, we determined the MOAP-1-interacting region of RASSF6 and the region implicated in the regulation of NFjB signaling. MOAP-1 binds to the N-terminal region of RASSF6, but not to the RA domain (Fig. S1) . Although the N-terminal region of RASSF6 is also implicated in the interaction with MDM2, MDM2 does not compete with MOAP-1 for the binding to RASSF6 and rather enhances it. NFjΒ signaling is suppressed by not only the RA domain but also RASSF6-del RA (Fig. S4) . These findings support that each domain of RASSF6 works as a distinct functional module and contributes to the role of the tumor suppressor RASSF6. 5 . The RA domain of RASSF6 induces apoptosis, senescence, and p53-target gene expression. (A) Control GFP, GFP-RASSF6-RA, or GFP-RASSF6-delRA was expressed in HCT116 cells. Twenty-four hours later, the cells were fixed and immunostained with anti-cytochrome C antibody. The nuclei were visualized with Hoechst 33342. GFP-RASSF6-RA induced the nuclear condensation and cytochrome C release, but control GFP or GFP-RASSF6-delRA did not (arrowheads). Fifty GFP-positive cells were observed and the cells with the nuclear condensation and cytochrome C release were counted. Three independent observations were analyzed. Bar, 10 lm. **P < 0.01; and ***P < 0.001. (B) GFP, GFP-RASSF6, or RASSF6-RA were expressed in TIG-3 cells by use of retrovirus vectors. The cells were transfected with control (siCont.) or p53-targeted siRNA (sip53). Five days later, the cells were fixed and analyzed by use of a senescence bgalactosidase-staining kit according to the manufacturer's protocol. Bar, 10 lm. (C) HCT116 cells were transfected with pCIneoGFP or pCIneoGFP-RASSF6-del RA. Twenty-four hours later, the cells were exposed to 25 JÁm À2 UV. Twenty-four hours later, the cells were fixed and analyzed as described (A). UV induced apoptosis in the cells expressing control GFP (the third panel, an arrowhead), but not in the cells expressing GFP-RASSF6-del RA (the fourth panel, an arrowhead). n.s., no significance; **P < 0.01; and ***P < 0.001. (D) HCT116 cells were transfected with pCIneoGFP, pCIneoGFP-RASSF6-RA, or pCIneoGFP-RASSF6-del RA. Twelve hours later, the cells were harvested.
qRT-PCR was performed by use of glyceraldehyde 3-phosphate dehydrogenase as a reference. The value for the cells expressing control GFP was set at 1.0. GFP-RASSF6-RA enhanced BTG2 and CDKN1A (p21) mRNAs. n.s, no significance; *P < 0.05; and **P < 0.01. 
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